Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics (NASDAQ: CADL) has announced a webcast and conference call scheduled for June 3, 2025, at 1:00PM ET to discuss positive Phase 3 clinical results for their CAN-2409 treatment in localized, intermediate-to-high risk prostate cancer. The results showed a statistically significant 30% reduction in disease recurrence compared to placebo when combined with standard-of-care radiation therapy.
The call will feature insights from principal investigators Dr. John E. Sylvester and Dr. Ronald F. Tutrone, Jr., following Dr. Theodore DeWeese's oral presentation at the 2025 ASCO Annual Meeting. Both featured specialists bring extensive experience in prostate cancer treatment and research, with over two decades of expertise in their respective fields.
Candel Therapeutics (NASDAQ: CADL), a clinical stage biopharmaceutical company developing biological immunotherapies for cancer treatment, has announced its participation in two major upcoming investor conferences:
1. Bank of America Securities 2025 Health Care Conference in Las Vegas: - Chief Scientific Officer Francesca Barone will present on May 14, 2025, at 4:20 PM PT - Location: Las Vegas, NV
2. Jefferies Global Healthcare Conference in New York: - President and CEO Paul Peter Tak will present on June 5, 2025, at 8:40 AM PT - Location: New York, NY
Live webcasts will be available on Candel's website under the Investors section, with replays archived for up to 90 days after the presentations.
Candel Therapeutics (Nasdaq: CADL) has announced that data from their phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer will be presented at the 2025 ASCO Annual Meeting. The presentation will feature results from a randomized, placebo-controlled study examining CAN-2409+prodrug combined with standard-of-care external beam radiation therapy (EBRT) for newly diagnosed localized prostate cancer.
The oral presentation will be delivered by Dr. Theodore DeWeese, Dean of Medical Faculty and CEO of Johns Hopkins Medicine, on June 3, 2025, during the Genitourinary Cancer session at McCormick Place Convention Center, Chicago. Full abstracts will be released on May 22, 2025.
Candel Therapeutics (CADL) has published Phase 1b clinical trial results in Neuro-Oncology, evaluating CAN-2409 plus valacyclovir and nivolumab combination with standard care in newly diagnosed high-grade glioma patients.
The trial enrolled 41 patients, with 35 completing the full treatment. Key findings include:
- Median overall survival of 15.1 months for the general population
- A subset of patients with methylated MGMT promoter and gross total tumor resection (n=6) achieved 30.6 months median survival
- Treatment showed immune activation at weeks 3 and 5, including increased naive and effector T cells
- No dose-limiting toxicities were observed for CAN-2409
While Candel is not pursuing CAN-2409 for high-grade glioma due to portfolio prioritization, the company is developing it for localized prostate cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.
Candel Therapeutics reported final survival data from its Phase 2a clinical trial of CAN-2409 in advanced Non-Small Cell Lung Cancer (NSCLC) patients who failed to respond to immune checkpoint inhibitor (ICI) treatment. The study showed remarkable results with median overall survival (mOS) of 24.5 months in the evaluable patient population, significantly exceeding the standard care outcomes.
Key findings include:
- 21.5 months mOS in patients with progressive disease despite ICI therapy, compared to 9.8-11.8 months with standard docetaxel chemotherapy
- 37% of patients survived beyond 2 years after CAN-2409 administration
- 69% of patients showed regression in uninjected tumors (abscopal effect)
- Non-squamous NSCLC patients showed superior outcomes with 25.4 months mOS
The treatment maintained a favorable safety profile throughout the extended follow-up period. The FDA has granted Fast Track Designation for CAN-2409 in combination with ICI treatment for stage III/IV NSCLC patients resistant to first-line PD-(L)1 inhibitor therapy.
Candel Therapeutics (Nasdaq: CADL) has formed a strategic commercial partnership with IDEA Pharma to advance commercialization efforts for CAN-2409. The partnership follows positive phase 3 data for CAN-2409 in intermediate-to-high risk, localized prostate cancer, which demonstrated:
- 30% decrease in disease recurrence
- Statistically significant improvement in disease-free survival
- Higher pathological complete response rate (80.4% vs 63.6% in placebo)
IDEA Pharma will provide strategic commercial input through 2026, supporting Candel's BLA submission for CAN-2409 in prostate cancer. The partnership grants Candel access to IDEA's dedicated team of oncology commercialization experts to optimize go-to-market strategy.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
